60239-18-1
Chemical Structure
Tetraxetan
Synonym(s): DOTA
- CAS No.: 60239-18-1
- Formula:C16H28N4O8
- Molecular Weight:404.42
IUPAC Name: 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid
InChIKey: WDLRUFUQRNWCPK-UHFFFAOYSA-N
SMILES: O=C(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1
Biological Activity: Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) [1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tetraxetan | 99.95% | Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tetraxetan (Standard) | ≥98% | Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Orcutt KD, et al. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol. 2011 Apr;13(2):215-21. [Content Brief]
- [2]. Decristoforo C, et al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1507-15. [Content Brief]
- [3]. Müller C, et al. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice. J Nucl Med. 2013 Jan;54(1):124-31. [Content Brief]
Keywords
